Statement from National HBPA CEO on FTC Order to Not Approve HISA Drug and Medication Rules
Statement from National HBPA CEO Eric Hamelback on the Federal Trade Commission’s order to not approve the Horseracing Integrity & Safety Authority’s Anti-Doping and Medication Control rules that were to go into effect Jan. 1:
“The recent FTC decision is another positive step forward for horsemen in our battle against the unconstitutional takeover of our industry. The strength of our legal arguments led to a unanimous decision in the Fifth Circuit, and now the FTC has done the right thing in declining to defy a federal court that has found HISA unconstitutional. The FTC order is clear: state law continues to govern medication issues until our final victory in this case.”
Eric J. Hamelback
CEO, The National HBPA
